EUVIMEDEUVIMED entdecken
Open Access

Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome

Artur Świerczek, William J Jusko iD

The Journal of Pharmacology and Experimental Therapeutics · 2023-03 · 384 (3) · 455-472

DOI: 10.1124/jpet.122.001477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-03. Verfasst von Artur Świerczek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York. Hauptthemen laut MEDLINE: Lipopolysaccharides, COVID-19. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dexamethasone (DEX) is a potent synthetic glucocorticoid used for the treatment of variety of inflammatory and immune-mediated disorders. The RECOVERY clinical trial revealed benefits of DEX therapy in COVID-19 patients. Severe SARS-CoV-2 infection leads to an excessive inflammatory reaction commonly known as a cytokine release syndrome that is associated with activation of the toll like receptor 4 (TLR4) signaling pathway. The possible mechanism of action of DEX in the treatment of COVID-19 is related to its anti-inflammatory activity arising from inhibition of cytokine production but may be also attributed to its influence on immune cell trafficking and turnover. This study, by means of pharmacokinetic/pharmacodynamic modeling, aimed at the comprehensive quantitative assessment of DEX effects in lipopolysaccharide-challenged rats and to describe interrelations among relevant signaling molecules in this animal model of cytokine release syndrome induced by activation of TLR4 pathway. DEX was administered in a range of doses from 0.005 to 2.25 mg·kg-1 in LPS-challenged rats. Serum DEX, corticosterone (CST), tumor necrosis factor α, interleukin-6, and nitric oxide as well as lymphocyte and granulocyte counts in peripheral blood were quantified at different time points. A minimal physiologically based pharmacokinetic/pharmacodynamic (mPBPK/PD) model was proposed characterizing the time courses of plasma DEX and the investigated biomarkers. A high but not complete inhibition of production of inflammatory mediators and CST was produced in vivo by DEX. The mPBPK/PD model, upon translation to humans, may help to optimize DEX therapy in patients with diseases associated with excessive production of inflammatory mediators, such as COVID-19. SIGNIFICANCE STATEMENT: A mPBPK/PD model was developed to describe concentration-time profiles of plasma DEX, mediators of inflammation, and immune cell trafficking and turnover in LPS-challenged rats. Interrelations among DEX and relevant biomarkers were reflected in the mechanistic model structure. The mPBPK/PD model enabled quantitative assessment of in vivo potency of DEX and, upon translation to humans, may help optimize dosing regimens of DEX for the treatment of immune-related conditions associated with exaggerated immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipopolysaccharidesCOVID-19HumansRatsAnimalsDexamethasoneToll-Like Receptor 4Cytokine Release SyndromeCOVID-19 Drug TreatmentSARS-CoV-2Anti-Inflammatory AgentsInflammationImmunityInflammation Mediators

Substanzen

LipopolysaccharidesDexamethasoneToll-Like Receptor 4Anti-Inflammatory AgentsInflammation Mediators

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York.
  • Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York wjjusko@buffalo.edu.

ORCID-Profile: William J Jusko

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Świerczek, A., & Jusko, W. J. (2023). Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome. The Journal of Pharmacology and Experimental Therapeutics, 384(3), 455-472. https://doi.org/10.1124/jpet.122.001477

Vancouver

Świerczek A, Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome. The Journal of Pharmacology and Experimental Therapeutics. 2023;384(3):455-472. doi:10.1124/jpet.122.001477

BibTeX
@article{wierczek2023,
  author = {Świerczek, Artur and Jusko, William J},
  title = {Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2023},
  volume = {384},
  number = {3},
  pages = {455--472},
  doi = {10.1124/jpet.122.001477}
}
Kostenlos starten →